紫杉醇联合替吉奥与奥沙利铂联合替吉奥在胃癌辅助化疗中的比较研究

doi:10.3969/j.issn.1006-6233.2020.07.025

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1386 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的:分析比较紫杉醇联合替吉奥与奥沙利铂联合替吉奥在胃癌(GC)辅助化疗中的的应用效果。方法:选取2016年10月至2018年10月我院诊治的73例GC晚期患者为主要研究对象,均经手术病理确诊。按照简单随机数字表法分为观察组(n=36,采用奥沙利铂+替吉奥化疗)和对照组(n=37,采用替吉奥+紫杉醇化疗)。观察比较两组的近期疗效及免疫功能指标变化;随访截止至2019年10月31日,记录无疾病进展生存期(PFS)总生存时间(OS),两组术后复发率及发生的不良反应。结果:两组疾病控制率、术后复发率、PFS、OS间差异均无统计学意义(P>0.05);与化疗前比,两组化疗后的Ig A、IgG及IgM指标均较化疗前有明显升高(P<0.05);而与对照组比,观察组化疗后的Ig A及IgG水平均有明显升高(P<0.01)。观察组中性粒细胞减少人数占比为25.71%,明显低于对照组的48.57%,差异有统计学意义(P<0.05)。结论:紫杉醇+替吉奥与奥沙利铂+替吉奥可获得相似的近期疗效及生存时间,但奥沙利铂+替吉奥更能改善GC患者的免疫功能,提高患者的耐受性,值得临床推广应用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	汪春梅
	周国志

关键词 ：胃癌, 紫杉醇, 奥沙利铂, 化疗, 替吉奥, 疗效

Abstract：Objective: To compare the effect of the combination of paclitaxel and oxaliplatin in the adjuvant chemotherapy of gastric cancer (GC). Methods: 73 patients with advanced GC diagnosed and treated in our hospital from October 2016 to October 2018 were selected as the main subjects. All of them were diagnosed by operation and pathology, and according to the simple random digital table method, divided into the observation group (n=36, chemotherapy of Oxaliposide and Tigiao) and the control group (n =37, chemotherapy of Tigiopaclitaxel and Tigiao).The recent curative effect and the change of the immune function index of the two groups were observed.The overall survival time (OS) of progression-free survival (PFS) was recorded as of October 31,2019, and also the recurrence rate of the two groups and the occurrence of the adverse reactions were recorded. Results: There was no significant difference between the two groups of disease control rate, the postoperative recurrence rate, the PFS and the OS (Pall> 0.05).The levels of Ig A, IgG and IgM after chemotherapy in the two groups were significantly higher than those before chemotherapy(Pall< 0.05).Compared with the control group, the levels of Ig A and IgG in the observation group were significantly higher than those in the control group (Pall< 0.01).The proportion of neutrophils in the observation group was 25.71%, which was significantly lower than that in the control group (48.57%,P < 0.05). Conclusion: The paclitaxel + tigecycline and oxaliplatin + teggio therapies can achieve similar near-term efficacy and survival time. But the oxaliplatin + teggio therapy can improve the immune function of the GC patients and improve the tolerance of the patients, and is worthy of clinical promotion and application.

Key words： Gastric cancer Paclitaxel Oxaliplatin Chemotherapy Tegio Curative effect

基金资助:江苏省自然科学基金项目,(编号:BK20170530)

通讯作者: 周国志

引用本文:

汪春梅, 周国志. 紫杉醇联合替吉奥与奥沙利铂联合替吉奥在胃癌辅助化疗中的比较研究[J]. 河北医学, 2020, 26(7): 1160-1164.
WANG Chunmei, ZHOU Guozhi. A Comparative Study of Paclitaxel Combined with Tigiao and Oxaliposide Combined with Tigio in Adjuvant Chemotherapy of Gastric Cancer. HeBei Med, 2020, 26(7): 1160-1164.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2020.07.025 或 http://www.hbyxzzs.cn/CN/Y2020/V26/I7/1160

[1] 施一鸣,季长风,刘松,等.胃癌不同EGFR表达状态的增强CT表现[J].医学影像学杂志,2019,29(3):425~430.
[2] 刘文静,赵艳秋,胡秀峰,等.紫杉醇脂质体联合替吉奥治疗晚期胃癌的有效性及安全性评价[J].郑州大学学报(医学版),2014,49(6):783~786.
[3] 宁洁,焦洋,李敏,等.替吉奥联合奥沙利铂一线治疗晚期结直肠癌的疗效及安全性研究[J].安徽医药,2017,21(9):1669~1672.
[4] 邹凤双,陈继甫,张艳军.胃癌根治术中吻合器吻合与手法单双层缝合吻合方式的效果比较[J].河北医学,2016,22(8):1352~1355.
[5] 郭萍,张军鹏,贺继东.胃癌患者原发病灶的组织学评价与新辅助化疗预后的相关性[J].国际肿瘤学杂志,2018,45(10):588~592.
[6] 常占国.吉西他滨联合替吉奥治疗晚期胆囊癌的疗效[J].实用临床医学,2018,19(12):18~19.
[7] 莫淼,杨佳柠,董超.阿特珠单抗联合白蛋白结合型紫杉醇治疗晚期三阴性乳腺癌的Ⅲ期临床试验-IMpassion130研究解读[J].中国癌症杂志,2019,29(4):313~320.
[8] 张伟鹏,徐元元,刘苇,等.FOLFOXIRI与SOX化疗方案治疗晚期结直肠癌的近期效果比较[J].肿瘤研究与临床,2018,30(8):548~552.
[9] 沈旭东,庄志祥,甘蕾,等.每周脂质体紫杉醇或奥沙利铂联合替吉奥方案治疗老年晚期胃癌的疗效及安全性分析[J].肿瘤防治研究,2016,43(5):86~89.
[10] 林锦源,杨建伟,高炜,等.胃癌术后氟尿嘧啶联合奥沙利铂或紫杉醇序贯替吉奥方案的临床观察[J].临床肿瘤学杂志,2018,23(6):559~562.
[11] 单永锋,陈艳.替吉奥联合奥沙利铂方案治疗老年胃癌对患者血清肿瘤标志物、基质金属蛋白酶及免疫功能的影响[J].海南医学院学报,2017,23(19):2720~2723.
[12] 王妹兴,肖谜.替吉奥分别联合紫杉醇与奥沙利铂在胃癌术后辅助化疗的应用比较[J].贵州医药,2018,42(3):297~299.